{"id": "neC-dNAAAAAJ", "citedby": 46374, "citedby5y": 14944, "hindex": 64, "hindex5y": 48, "i10index": 66, "i10index5y": 62, "coauthors": [], "name": "Richard A. Larson", "affiliation": "professor of Medicine, The University of Chicago", "interests": ["medicine"], "cites_per_year": {"1992": 150, "1993": 135, "1994": 157, "1995": 194, "1996": 208, "1997": 181, "1998": 222, "1999": 189, "2000": 250, "2001": 295, "2002": 482, "2003": 925, "2004": 1112, "2005": 1157, "2006": 1289, "2007": 1669, "2008": 2085, "2009": 2412, "2010": 2892, "2011": 3569, "2012": 3411, "2013": 3400, "2014": 3339, "2015": 3449, "2016": 3175, "2017": 2852, "2018": 2482, "2019": 2083, "2020": 892}, "publications": [{"bib": {"title": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:YOwf2qJgpHMC", "citedby": "3908"}, {"bib": {"title": "Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia", "year": "2006"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:qjMakFHDy7sC", "citedby": "3708"}, {"bib": {"title": "Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:RHpTSmoSYBkC", "citedby": "3118"}, {"bib": {"title": "Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic \u2026", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:hFOr9nPyWt4C", "citedby": "2210"}, {"bib": {"title": "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B", "year": "2002"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:e5wmG9Sq2KIC", "citedby": "1803"}, {"bib": {"title": "European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013", "year": "2013"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:qUcmZB5y_30C", "citedby": "1791"}, {"bib": {"title": "Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid \u2026", "year": "2002"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:LkGwnXOMwfcC", "citedby": "1720"}, {"bib": {"title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:4JMBOYKVnBMC", "citedby": "1671"}, {"bib": {"title": "Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at \u2026", "year": "2002"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:_FxGoFyzp5QC", "citedby": "1384"}, {"bib": {"title": "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", "year": "2000"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:MXK_kJrjxJIC", "citedby": "1282"}, {"bib": {"title": "Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse", "year": "2001"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:5nxA0vEk-isC", "citedby": "1014"}, {"bib": {"title": "International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed \u2026", "year": "2009"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:Y0pCki6q_DkC", "citedby": "777"}, {"bib": {"title": "Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study", "year": "2015"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:Wp0gIr-vW9MC", "citedby": "733"}, {"bib": {"title": "IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:j3f4tGmQtD8C", "citedby": "720"}, {"bib": {"title": "Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer \u2026", "year": "2001"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:bEWYMUwI8FkC", "citedby": "704"}, {"bib": {"title": "Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study", "year": "2006"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:iH-uZ7U-co4C", "citedby": "696"}, {"bib": {"title": "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia \u2026", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:maZDTaKrznsC", "citedby": "694"}, {"bib": {"title": "A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811", "year": "1995"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:M3ejUd6NZC8C", "citedby": "694"}, {"bib": {"title": "Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:mVmsd5A6BfQC", "citedby": "633"}, {"bib": {"title": "Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:qxL8FJ1GzNcC", "citedby": "631"}, {"bib": {"title": "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B", "year": "2006"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:r0BpntZqJG4C", "citedby": "588"}, {"bib": {"title": "Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations", "year": "1993"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:hqOjcs7Dif8C", "citedby": "575"}, {"bib": {"title": "MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia", "year": "2007"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:_Qo2XoVZTnwC", "citedby": "541"}, {"bib": {"title": "Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: a unique cytogenetic\u2013clinicopathological association", "year": "1983"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:ULOm3_A8WrAC", "citedby": "527"}, {"bib": {"title": "Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of \u2026", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:9ZlFYXVOiuMC", "citedby": "524"}, {"bib": {"title": "Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow \u2026", "year": "2011"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:IjCSPb-OGe4C", "citedby": "500"}, {"bib": {"title": "Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated \u2026", "year": "2005"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:eQOLeE2rZwMC", "citedby": "499"}, {"bib": {"title": "Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997", "year": "2007"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:0EnyYjriUFMC", "citedby": "492"}, {"bib": {"title": "Distinct microRNA expression profiles in acute myeloid leukemia with common translocations", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:Tyk-4Ss8FVUC", "citedby": "488"}, {"bib": {"title": "MicroRNA expression in cytogenetically normal acute myeloid leukemia", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:TQgYirikUcIC", "citedby": "481"}, {"bib": {"title": "Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia", "year": "1984"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:k_IJM867U9cC", "citedby": "473"}, {"bib": {"title": "What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group \u2026", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:YsMSGLbcyi4C", "citedby": "470"}, {"bib": {"title": "Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase", "year": "2007"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:KlAtU1dfN6UC", "citedby": "459"}, {"bib": {"title": "Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B \u2026", "year": "2002"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:QIV2ME_5wuYC", "citedby": "422"}, {"bib": {"title": "Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33\u2010positive acute myeloid leukemia in first recurrence", "year": "2005"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:3fE2CSJIrl8C", "citedby": "417"}, {"bib": {"title": "Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study", "year": "2002"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:dhFuZR0502QC", "citedby": "415"}, {"bib": {"title": "Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results", "year": "2011"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:zYLM7Y9cAGgC", "citedby": "413"}, {"bib": {"title": "Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997", "year": "2007"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:TFP_iSt0sucC", "citedby": "407"}, {"bib": {"title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia with resistance or \u2026", "year": "2007"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:roLk4NBRz8UC", "citedby": "376"}, {"bib": {"title": "Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome: Presented in part at the meeting of the American Society of \u2026", "year": "2000"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:UebtZRa9Y70C", "citedby": "356"}, {"bib": {"title": "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic \u2026", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:aqlVkmm33-oC", "citedby": "353"}, {"bib": {"title": "Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression \u2026", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:IWHjjKOFINEC", "citedby": "350"}, {"bib": {"title": "TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study", "year": "2011"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:ZeXyd9-uunAC", "citedby": "347"}, {"bib": {"title": "Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience", "year": "1999"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:Se3iqnhoufwC", "citedby": "340"}, {"bib": {"title": "Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710", "year": "2010"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:HDshCWvjkbEC", "citedby": "339"}, {"bib": {"title": "Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long-term remission", "year": "1993"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:kNdYIx-mwKoC", "citedby": "336"}, {"bib": {"title": "Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)", "year": "1992"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:L8Ckcad2t8MC", "citedby": "334"}, {"bib": {"title": "Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t (8; 21) differ from those of patients with inv (16): a Cancer and Leukemia Group B \u2026", "year": "2005"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:W7OEmFMy1HYC", "citedby": "330"}, {"bib": {"title": "Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk \u2026", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:mB3voiENLucC", "citedby": "328"}, {"bib": {"title": "Prevalence of the Inactivating 609C\u2192T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related \u2026", "year": "1999"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:4DMP91E08xMC", "citedby": "326"}, {"bib": {"title": "Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II", "year": "1993"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:R3hNpaxXUhUC", "citedby": "325"}, {"bib": {"title": "Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia \u2026", "year": "2006"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:-f6ydRqryjwC", "citedby": "312"}, {"bib": {"title": "Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung", "year": "1987"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:_kc_bZDykSQC", "citedby": "289"}, {"bib": {"title": "BAALC expression predicts clinical outcome of de novo acute  myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia  Group B Study", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:Zph67rFs4hoC", "citedby": "288"}, {"bib": {"title": "Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for \u2026", "year": "2006"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:8k81kl-MbHgC", "citedby": "284"}, {"bib": {"title": "A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111", "year": "1998"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:4TOpqqG69KYC", "citedby": "282"}, {"bib": {"title": "Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes", "year": "1986"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:hC7cP41nSMkC", "citedby": "278"}, {"bib": {"title": "Wilms\u2019 tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:7PzlFSSx8tAC", "citedby": "276"}, {"bib": {"title": "International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular \u2026", "year": "2008"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:isC4tDSrTZIC", "citedby": "270"}, {"bib": {"title": "Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases", "year": "1993"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:UeHWp8X0CEIC", "citedby": "264"}, {"bib": {"title": "Deletions of interferon genes in acute lymphoblastic leukemia", "year": "1990"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:WF5omc3nYNoC", "citedby": "264"}, {"bib": {"title": "Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders", "year": "1986"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:ufrVoPGSRksC", "citedby": "263"}, {"bib": {"title": "Studies of the human c-myb gene and its product in human acute leukemias", "year": "1986"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:u-x6o8ySG0sC", "citedby": "135"}, {"bib": {"title": "Elitek\u2122\u2013rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002", "year": "2003"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:blknAaTinKkC", "citedby": "98"}, {"bib": {"title": "New high-performance liquid chromatographic assay for plasma doxorubicin", "year": "1985"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:2osOgNQ5qMEC", "citedby": "24"}, {"bib": {"title": "Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors", "year": "2013"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:d1gkVwhDpl0C", "citedby": "13"}, {"bib": {"title": "Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects", "year": "2016"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:hMod-77fHWUC", "citedby": "6"}, {"bib": {"title": "Tumor lysis syndrome: prevention and treatment", "year": "2015"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:u5HHmVD_uO8C", "citedby": "3"}, {"bib": {"title": "Prevention and management of anthracycline cardiotoxicity", "year": "2016"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:M3NEmzRMIkIC", "citedby": "2"}, {"bib": {"title": "Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and \u2026"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:YFjsv_pBGBYC", "citedby": "1"}, {"bib": {"title": "GRAPHICS View All"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:BqipwSGYUEgC", "citedby": "0"}, {"bib": {"title": "GRAPHICS View All"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:NMxIlDl6LWMC", "citedby": "0"}, {"bib": {"title": "Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity"}, "source": "citations", "id_citations": "neC-dNAAAAAJ:JV2RwH3_ST0C", "citedby": "0"}]}